SciBase Holding AB Secures US FDA Approval to Expand Nevisense Use Beyond Dermatologists
U.S. Food and Drug Administration clears expanded labelling for Nevisense, enabling trained healthcare professionals to perform procedures, improving clinic workflow integration and supporting broader melanoma diagnostic access across the United States.
Nevisense Device | 03/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy